The little-known provision of Obamacare that could have a big, bad impact

December 5, 2012 by MassDevice

Sempus Biosciences David Lucchino on the 2.3%medical device excise tax.

doctor illustration

by David Lucchino, published by WBUR Boston's Cognoscenti blog

David Lucchino: The 2.3 percent excise tax on the medical devices sector would hamper innovation, force layoffs and cripple loss-making start-ups. (Alex E. Proimos/flickr)

Passing through Kendall Square one might never get a sense of the medical research and innovation going on here. But when my business partner and I founded Semprus BioSciences, a medical device company, we had an inkling it was the place to be. It turned out to be one of our best decisions.

Sign up to get our free newsletters delivered right to your inbox.

In Kendall, our neighbors are some of the smartest people in the world – innovative companies that create better disease detection and whose therapies and products help treat cystic fibrosis, cancer, diabetes and many other life threatening diseases.

Dr. Robert Langer's research lab at the MIT, for example, was the subject of a recent article in The New York Times:

"The Langer Lab is on the front lines of turning discoveries made in the lab into a range of drugs and drug delivery systems. Without this kind of technology transfer, the thinking goes, scientific discoveries might well sit on the shelf, stifling innovation."